News
![Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine: https://www.irw-press.at/prcom/images/messages/2023/70633/Accesswire-Neurimmune_220523.001.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1lWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4eed58c15c2cef3ad074a955184a356e9489f7b5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Accesswire-Neurimmune_220523.001.jpeg?locale=us)
Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine
Results also presented during late-breaking session at ESC Heart Failure congress 2023
ZURICH, SWITZERLAND / ACCESSWIRE / May 20, 2023 / Neurimmune announced today that primary results of
![Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?: https://www.marketbeat.com/logos/articles/med_20230518141428_is-pfizers-seagen-deal-in-jeopardy-amid-antitrust.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNk1UYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--828975049b596f383745f5396fd915be2235140a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518141428_is-pfizers-seagen-deal-in-jeopardy-amid-antitrust.jpg?locale=us)
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Pfizer Inc. (NYSE: PFE) continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.’s (NASDAQ: AMGN) planned acquisition of Horizon
![Zoetis Declares New Dividend, Hinting At Undervaluation: https://www.marketbeat.com/logos/articles/med_20230518102050_zoetis-declares-new-dividend-hinting-at-undervalua.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEVTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3c586cb6fc0711a2c928535d3df9a038565bda71/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518102050_zoetis-declares-new-dividend-hinting-at-undervalua.jpg?locale=us)
Zoetis Declares New Dividend, Hinting At Undervaluation
Zoetis (NYSE: ZTS) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company's first quarter 2023 announcements. Even
![Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market: https://www.marketbeat.com/logos/articles/med_20230518072301_pharma-giants-novartis-lilly-merck-and-novo-outper.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMHNTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1a176b59739d73a4cead553b293226e8f0f15add/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518072301_pharma-giants-novartis-lilly-merck-and-novo-outper.jpg?locale=us)
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Big pharmaceutical stocks, including Novartis AG (NYSE: NVS), Eli Lilly & Co. (NYSE: LLY), Merck & Co. (NYSE: MRK), and Novo Nordisk A/S (NYSE: NVO) have been outperforming the broader market
![Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings: https://www.marketbeat.com/logos/articles/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGtTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fe1fa8a76cffa1e1d1a7a5af6f98fc7532bc5f23/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg?locale=us)
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report.
Net income of $3.05 a
![How to Invest in Telehealth and Telemedicine Stocks: https://www.marketbeat.com/logos/articles/med_20230517114005_telemedicine-stocks.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUVSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e796a1efe22a38a79c5853f0e22bb11c6fbef543/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230517114005_telemedicine-stocks.png?locale=us)
How to Invest in Telehealth and Telemedicine Stocks
Coming into prominence during the COVID-19 pandemic, telemedicine stocks saw increases in price and profitability in the past five years. As relaxed government regulations allowed service
![The Turnaround for Weight Watchers is Taking Shape: https://www.marketbeat.com/logos/articles/med_20230514180546_charty-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGdPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff351f66c02189ec9ff23c0f8c44db4d7d59a6ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514180546_charty-ww.jpg?locale=us)
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares collapsed (26%) as Artal Group S.A
![Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy: https://www.marketbeat.com/logos/articles/med_20230516050346_sarepta-soars-31-as-fda-panel-backs-muscular-dystr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVFPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a31cb6b4ac8302cca8e5e70e3f6ee5c85d029040/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230516050346_sarepta-soars-31-as-fda-panel-backs-muscular-dystr.jpg?locale=us)
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
Sarepta Therapeutics Inc. (NASDAQ: SRPT) jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company’s experimental gene therapy to treat Duchenne
![UnitedHealth Group is an AI Stock That Isn't Beating Expectations: https://www.marketbeat.com/logos/articles/med_20230515071148_unitedhealth-group-is-an-ai-stock-that-isnt-beatin.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzRNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--24e907afce9c48e7893a6e3910721cb7d1961c9b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230515071148_unitedhealth-group-is-an-ai-stock-that-isnt-beatin.jpg?locale=us)
UnitedHealth Group is an AI Stock That Isn't Beating Expectations
UnitedHealth Group Inc. (NYSE: UNH) is down 7.2% in 2023. The health maintenance organization (HMO) sector in general is lagging the market. So, investors may simply be taking a pause on a stock
![Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales: https://www.marketbeat.com/logos/articles/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2tCYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--26208beaff1e53954dadcf470598a9dc71a7ffae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg?locale=us)
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
Net income tumbled by 12% to $10.09 a
![Will Forced Divesture Of Grail Boost Illumina Shareholder Value?: https://www.marketbeat.com/logos/articles/med_20230502151412_will-forced-divesture-of-grail-boost-illumina-shar.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUQ5YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--14e4acba5cef49f60ce54a50415fafe59eec22f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230502151412_will-forced-divesture-of-grail-boost-illumina-shar.jpg?locale=us)
Will Forced Divesture Of Grail Boost Illumina Shareholder Value?
The phrase, “I’m from the government and I’m here to help” has a well-deserved reputation as a terrifying phrase, but for medical researcher Illumina Inc. (NASDAQ: ILMN), which specializes in DNA
![Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding: https://www.marketbeat.com/logos/articles/med_20230502115431_chart-canf.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMi84YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9fa461efe4512eccd853447afe3a816d6464059f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230502115431_chart-canf.jpg?locale=us)
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction. It
![High-Yield Pfizer Falls Off The COVID Cliff, And Survives: https://www.marketbeat.com/logos/articles/med_20230502093017_chart-pfe-522023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1Q4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c311c303e106fc0d8d8d3da758dae9bcd621a7f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230502093017_chart-pfe-522023.png?locale=us)
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is
![Can Butterfly Network Spread its Wings in 2023?: https://www.marketbeat.com/logos/articles/med_20230430132321_chart-blfy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFg4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfef5abc05093dde9e172fd01528b35863eeab8f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230430132321_chart-blfy.jpg?locale=us)
Can Butterfly Network Spread its Wings in 2023?
Butterfly Network Inc. (NYSE: BFLY) is a medical imaging solutions company that makes point-of-demand portable ultrasound devices to bring medical imaging to healthcare providers at a deep
![Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal: https://www.marketbeat.com/logos/articles/med_20230425102047_chart-viri.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNi84YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e765016dc4874369137a4917d444f93993635bd3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230425102047_chart-viri.jpg?locale=us)
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune
![Why Legend Biotech Stock Is Having Its Best Month Yet: https://www.marketbeat.com/logos/articles/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2I4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e0fb704b76cef35f42fad2a7857b3b605b658608/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg?locale=us)
Why Legend Biotech Stock Is Having Its Best Month Yet
Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.
On April 19th, a
![Medtronic: Reversal In-Play For This High-Yield Stock: https://www.marketbeat.com/logos/articles/med_20230424105754_chart-mdt-4242023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2o4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32cd92c5fc0f9b67315b0c58c997d9983718d809/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230424105754_chart-mdt-4242023.png?locale=us)
Medtronic: Reversal In-Play For This High-Yield Stock
The med-tech companies have gotten a lot of attention lately, and Medtronic (NYSE: MDT) is included. The rebound in procedures and healthcare services following the pandemic drives a rebound in
![Weight Watchers Reshapes Itself with a Game-Changer Acquisition: https://www.marketbeat.com/logos/articles/med_20230411112556_chartt-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVBzYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d9fc96dd5bcfbc7ab9a86816e6a4fd4a7aa020a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230411112556_chartt-ww.jpg?locale=us)
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management food and services provider WW International Inc. (NYSE: WW) stock took a 25% spike as it closed its acquisition of telehealth weight loss platform provider Sequence Inc. WW
![BioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324/DB-1311 bei Prostatakrebshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324/DB-1311 bei Prostatakrebs
- Der Status basiert auf präklinischen Daten und Daten aus einer laufenden Phase-1/2-Studie für BNT324/DB-1311; vorläufige klinische Phase-1/2-Daten zeigten eine Anti-Tumor-Aktivität und ein
![Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom
- Erste Daten aus einer laufenden Phase-2-Studie zeigten eine 12-Monats-Gesamtüberlebensrate von 69 % und ein medianes Gesamtüberleben von 17,5 Monaten bei Patientinnen und Patienten mit
BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten
MAINZ, Deutschland, 21. Mai 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom
Accumulus Synergy sponsert bahnbrechenden Datenstandard für das Gesundheitswesen und macht Fortschritte auf dem Weg zu einer globalen Akte
Der gemeinnützige Branchenverband Accumulus Synergy ist Hauptsponsor und Finanzier eines neu veröffentlichten Datenstandards, der den Datenaustausch rationalisiert und zu einem besser vernetzten und
![BioNTech veröffentlicht am 6. Mai 2024 Ergebnisse für das erste Quartal 2024 und informiert über operativen Fortschritthttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
BioNTech veröffentlicht am 6. Mai 2024 Ergebnisse für das erste Quartal 2024 und informiert über operativen Fortschritt
MAINZ, Deutschland, 22. April 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 6. Mai 2024, die Ergebnisse für das erste Quartal 2024
![Unispace Group kündigt Ernennung eines neuen CEO für den EMEA-Raum an: https://ml.globenewswire.com/Resource/Download/7e7d8e2e-174d-434c-bfa5-3a489af017a5/image2.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWwzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--799837d6fb9b21bc596aad5e10f75d30c5ede1ee/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/image2.jpeg?locale=us)
Unispace Group kündigt Ernennung eines neuen CEO für den EMEA-Raum an
LONDON, April 17, 2024 (GLOBE NEWSWIRE) -- Die Unispace Group gibt heute die Einstellung von Rob Frank als CEO, Corporate Interiors, EMEA, mit Sitz in London sowie wichtige Ergänzungen des
Drei-Jahres-Follow-up-Daten aus Phase-1-Studie mit individualisiertem mRNA-Immuntherapie-Kandidaten zeigen eine anhaltende Immunantwort und ein verringertes Rückfallrisiko bei einigen Patienten mit reseziertem Bauchspeicheldrüsenkrebs
- Drei-Jahres-Follow-up-Daten aus einer nichtkommerziellen Phase-1-Studie mit dem individualisierten mRNA-basierten Krebsimpfstoff-Kandidaten Autogene Cevumeran (BNT122, RO7198457) bei Patientinnen